FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 356:1268-1269 March 22, 2007 Number 12 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Poole, C. J. PubMed Citation

To the Editor: Poole et al. (Nov. 2 issue)¹ conclude that patients with breast cancer benefit from the addition of four cycles of epirubicin to cyclophosphamide, methotrexate, and fluorouracil (CMF) in the adjuvant setting. In contrast to previously published data, the dose intensity of CMF did not seem to play a role.

Patients with breast cancer were included in the study irrespective of age, nodal status, or estrogen-receptor status. The degree of aggressiveness of the chemotherapy was not tailored to the risk of recurrence. The role of tamoxifen could not be evaluated because for many patients, neither hormone-receptor status nor . . . [Full Text of this Article]

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.